Iovance Biotherapeutics (IOVA) Long-Term Debt Issuances (2011 - 2021)
Iovance Biotherapeutics' (IOVA) quarterly Long-Term Debt Issuances came in at $1.0 million in Q1 2021, down 56.9% quarter-over-quarter from $2.3 million in Q4 2011.
Powered by 
Analysis
Iovance Biotherapeutics (IOVA) Long-Term Debt Issuances (2011 - 2021) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Long-Term Debt Issuances for 2 consecutive years, with $1.0 million the latest figure, recorded in Q1 2021.
- On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $1.0 million in Q1 2021; TTM through Dec 2021 was $1.0 million, a N/A change from a year earlier, with the FY2021 full-year figure at $1.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances was $1.0 million for Q1 2021 at Iovance Biotherapeutics, down from $2.3 million in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $1.0 million in Q1 2021 and troughed at $1.0 million in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | Taysha Gene Therapies | 1.97 Bn | 1.97 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2021 | 1.00 Mn |
| Dec 31, 2011 | 2.32 Mn |
| Sep 30, 2011 | 2.35 Mn |
| Jun 30, 2011 | -50,000.00 |